tiprankstipranks
Advertisement
Advertisement

AVBP Stock Latest News

ArriVent’s Firmonertinib Seen as Differentiated EGFR Inhibitor Ahead of FURVENT Readout; Buy Rating Reiterated with Unchanged $42 Price Target
RatingsArriVent’s Firmonertinib Seen as Differentiated EGFR Inhibitor Ahead of FURVENT Readout; Buy Rating Reiterated with Unchanged $42 Price Target
6h ago
AVBP
ArriVent’s Emerging CDH17-Targeted ADC Pipeline Supports Maintained Buy Rating and $45 Price Target
PremiumRatings
ArriVent’s Emerging CDH17-Targeted ADC Pipeline Supports Maintained Buy Rating and $45 Price Target
9d ago
AVBP
ArriVent BioPharma Stockholders Back Board and Auditor Slate
PremiumCompany Announcements
ArriVent BioPharma Stockholders Back Board and Auditor Slate
23d ago
8K
AVBP
ArriVent’s MRG007 Phase I Trial Progress Adds Long-Term Option Value for AVBP Investors
PremiumCompany Announcements
ArriVent’s MRG007 Phase I Trial Progress Adds Long-Term Option Value for AVBP Investors
1M ago
AVBP
Analyst Reiterates Buy on ArriVent, Maintains $42 Price Target on Firlotinib Confidence After Sunvozertinib Data
PremiumRatings
Analyst Reiterates Buy on ArriVent, Maintains $42 Price Target on Firlotinib Confidence After Sunvozertinib Data
1M ago
AVBP
ArriVent Biopharma assumed with a Buy at Truist
PremiumThe FlyArriVent Biopharma assumed with a Buy at Truist
2M ago
AVBP
ArriVent Biopharma price target lowered to $43 from $45 at Citi
Premium
The Fly
ArriVent Biopharma price target lowered to $43 from $45 at Citi
2M ago
AVBP
ArriVent Reaffirmed at Buy as Lead Asset Nears 2026 Phase 3 Readout; $42 Price Target Maintained
Premium
Ratings
ArriVent Reaffirmed at Buy as Lead Asset Nears 2026 Phase 3 Readout; $42 Price Target Maintained
2M ago
AVBP
ArriVent BioPharma Updates At-The-Market Equity Offering Program
PremiumCompany Announcements
ArriVent BioPharma Updates At-The-Market Equity Offering Program
2M ago
8K
AVBP
ArriVent Biopharma reports Q1 EPS (96c), consensus (89c)
PremiumThe Fly
ArriVent Biopharma reports Q1 EPS (96c), consensus (89c)
2M ago
AVBP
ArriVent BioPharma, Inc. (AVBP) Q1 Earnings Cheat Sheet
PremiumPre-Earnings
ArriVent BioPharma, Inc. (AVBP) Q1 Earnings Cheat Sheet
2M ago
AVBP
ArriVent Biopharma announces FDA clearance of ARR-002 NDA
PremiumThe Fly
ArriVent Biopharma announces FDA clearance of ARR-002 NDA
2M ago
AVBP
Buy Rating Reaffirmed on ArriVent as Firmonertinib Data Boost Confidence; $42 Price Target Maintained
PremiumRatingsBuy Rating Reaffirmed on ArriVent as Firmonertinib Data Boost Confidence; $42 Price Target Maintained
3M ago
AVBP
Citi ups ArriVent target, opens ‘upside 90-day catalyst watch’
Premium
The Fly
Citi ups ArriVent target, opens ‘upside 90-day catalyst watch’
3M ago
AVBP
ArriVent Biopharma price target raised to $45 from $37 at B. Riley
Premium
The Fly
ArriVent Biopharma price target raised to $45 from $37 at B. Riley
4M ago
AVBP
ArriVent Highlights Next-Generation Oncology Data at AACR 2026
PremiumCompany Announcements
ArriVent Highlights Next-Generation Oncology Data at AACR 2026
4M ago
8K
AVBP
ArriVent Biopharma assumed with a Buy at BTIG
PremiumThe Fly
ArriVent Biopharma assumed with a Buy at BTIG
4M ago
AVBP
ArriVent: Undervalued EGFR Franchise With Pivotal Firmonertinib Upside and Emerging ADC Optionality Driving Buy Rating and $42 Target
PremiumRatings
ArriVent: Undervalued EGFR Franchise With Pivotal Firmonertinib Upside and Emerging ADC Optionality Driving Buy Rating and $42 Target
4M ago
AVBP
ArriVent Biopharma price target raised to $50 from $44 at Oppenheimer
PremiumThe Fly
ArriVent Biopharma price target raised to $50 from $44 at Oppenheimer
4M ago
AVBP
ArriVent Biopharma price target raised to $44 from $42 at H.C. Wainwright
PremiumThe FlyArriVent Biopharma price target raised to $44 from $42 at H.C. Wainwright
4M ago
AVBP
ArriVent Biopharma price target raised to $33 from $31 at Citi
Premium
The Fly
ArriVent Biopharma price target raised to $33 from $31 at Citi
4M ago
AVBP
Omega takes new stake in Rocket Companies, exits ArriVent Biopharma
Premium
The Fly
Omega takes new stake in Rocket Companies, exits ArriVent Biopharma
5M ago
ET
ABR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >